Internal Medicine, Rheumatology · Visalia, CA
NPI
1437412129
Since 2012
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
220 S Akers St Ste D
Visalia, CA, 93291
Phone (559) 732-1648
Groups this clinician bills Medicare through
Medicare paid, 2024
$404K
39,478 services
Medicare patients, 2024
566
Average age 76
Drug cost, 2024
$15.9M
7,829 prescriptions
Company payments, 2025
$1,395
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Srikanth Naramala was code J3111 (injection, romosozumab-aqqg, 1 mg), 21,070 times for 85 patients. In total Srikanth Naramala billed 39,478 services in 26 codes, and Medicare paid $404K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-10-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 21,070 | 85 | $7.84 | $165K |
| J3262 Injection, tocilizumab, 1 mg | Office | 6,540 | 14 | $4.42 | $29K |
| J0897 Injection, denosumab, 1 mg | Office | 5,886 | 224 | $18.77 | $110K |
| 96372 Injection Administration | Office | 1,218 | 357 | $10.60 | $13K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 1,089 | 39 | $21.53 | $23K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 600 | 22 | $0.21 | $129 |
| 96415 Chemotherapy Administration | Office | 317 | 67 | $22.37 | $7,092 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 274 | 106 | $3.20 | $878 |
| 96413 Chemotherapy Administration | Office | 271 | 82 | $99.97 | $27K |
| 96365 Intravenous Infusion, Hydration | Office | 264 | 169 | $47.57 | $13K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 172 | 53 | $0.47 | $81.5 |
| J9312 Injection, rituximab, 10 mg | Office | 122 | 19 | $47.89 | $5,842 |
| 96375 Injection Administration | Office | 102 | 28 | $12.63 | $1,288 |
| J1885 Injection, ketorolac tromethamine, per 15 mg | Office | 101 | 26 | $0.51 | $51.07 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 52 | 28 | $0.62 | $32.09 |
By year: 2022 $881K for 76,675 services; 2023 $2.9M for 258,471 services; 2024 $404K for 39,478 services.
Medicare prescription drug claims, 2024
In 2024, the drug Srikanth Naramala prescribed most often to Medicare patients was Evenity (2 Syringes) (Romosozumab-Aqqg), with 728 prescriptions and refills. In total Srikanth Naramala wrote 7,829 Medicare prescriptions that cost $15.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Evenity (2 Syringes) Romosozumab-Aqqg | 728 | 731 | 120 | $1.7M |
| Methotrexate Methotrexate Sodium | 578 | 1,366 | 190 | $15K |
| Prednisone Generic | 408 | 708 | 152 | $2,936 |
| Hydroxychloroquine Sulfate Generic | 360 | 903 | 122 | $14K |
| Prolia Denosumab | 354 | 2,121 | 259 | $578K |
| Gabapentin Generic | 282 | 574 | 137 | $3,874 |
| Alendronate Sodium Generic | 261 | 627 | 90 | $2,137 |
| Diclofenac Sodium Generic | 253 | 320 | 123 | $182K |
| Xeljanz Xr Tofacitinib Citrate | 227 | 257 | 36 | $1.4M |
| Enbrel Sureclick Etanercept | 227 | 246 | 29 | $1.8M |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 212 | 213 | 46 | $5,310 |
| Humira Pen Adalimumab | 205 | 217 | 33 | $1.4M |
| Remicade Infliximab | 184 | 302 | 39 | $962K |
| Baclofen Generic | 173 | 282 | 90 | $2,259 |
| Zoledronic Acid Zoledronic Acid/Mannitol-Water | 149 | 1,074 | 149 | $15K |
Brand drugs: 3,449 claims; generic drugs: 4,346 claims; opioid claims: 372.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Srikanth Naramala $1,395 ($1,395 in general payments such as food, travel and fees) from 10 companies. The largest payer was Abbvie Inc. with $768.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 58 | $768 |
| Amgen Inc. AMGN | 16 | $236 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $95.05 |
| Pfizer Inc. PFE | 4 | $76.6 |
| Radius Health, Inc. | 3 | $73.69 |
| GlaxoSmithKline, LLC. GSK | 2 | $48.27 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $34.29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $29.99 |
| CSL Behring CSL.AX | 1 | $18.95 |
| UCB, Inc. UCB.BR | 1 | $15.13 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.